from DrRathFoundation Website
Asserting that the entire pharmaceutical industry is "on the brink of terminal decline," Stott described how research and development (R&D) returns in drug development now stand at just 3.2 percent and could potentially reach zero by the year 2020.
To put it simply, this means that each dollar spent on R&D by drug companies would merely result in an income of a dollar.
In other words,
Significantly, therefore, according to business website Forbes, Stott's data,
The implication of this
is that the beginning of the end for the 'Business
with Disease' may soon be in sight.
Describing how the return on investment in pharma R&D is rapidly declining, Stott states that the reasons for this include,
Putting all this together, Stott predicts that falls in the average return on investment will result in the entire pharma industry beginning to contract within the next two or three years.
By the year 2040 the annual value of the industry's total global sales may have fallen back to what it was in 1990. This would represent a catastrophic reduction in revenue of around 90 percent.
Tellingly, therefore, Stott describes the pharma business model as "broken," adding that it is,
He concludes that the industry "will not be around forever" and that it must "adapt or die."
Even then, however, he says it would still face,
Ultimately, of course, given that drugs don't address the root causes of diseases, but only their symptoms, the major breakthrough that pharma investors are hoping for will not occur.
Assuming therefore that Stott is correct in his analysis, which, as Forbes says,
...then a major rethink
in the design of our current healthcare systems could soon be just
around the corner.
Based on these science-based natural health approaches, which directly focus on the chronic deficiencies of micronutrients that are the root causes of chronic diseases, major killers such as,
...and others, could soon be brought under control.
The terminal decline of the pharma industry thus has the potential to become the trigger for implementing a truly preventative system of healthcare that saves millions of lives.
In this respect, it is interesting that, in analyzing the current situation, Stott turns to Darwin's theory of evolution and suggests that its central principle applies just as much to companies and industries as it does to the species of life:
Given that the pharma industry has consistently shown itself to be incapable of adapting its business model to focus on the root causes of chronic diseases, its terminal decline would appear to be inevitable.
Far-reaching as the ramifications of this outcome may be, they open the door to our reaching the goal of Health for All and reducing today's most common diseases to a fraction of their current incidence.
It won't please pharma
investors, but the next few years could potentially become
the gateway to a healthier world...